October 2009
M T W T F S S
« Sep   Nov »
 1234
567891011
12131415161718
19202122232425
262728293031  
Media Partnership

Archives

Minimizing Brain Damage by Speeding The Delivery of Post-Stroke Countermeasures

A new device from NeuroInterventions, Inc., is designed to minimize brain damage by dramatically speeding the delivery of post-stroke countermeasures.

“Stroke is the third most frequent cause of death, and the number-one cause of permanent disability,” says NeuroInterventions President and COO Michele Migliuolo [mil-u-OLO]. “When a clot blocks the flow of oxygen-rich blood in the brain, [...]

Children to Reduce Their Abdominal Pain With Guided Imagery Treatment

Children with functional abdominal pain who used audio recordings of guided imagery at home in addition to standard medical treatment were almost three times as likely to improve their pain problem, compared to children who received standard treatment alone.

And those benefits were maintained six months after treatment ended, a new study by University of North [...]

Bio-Matrix Scientific Group Provides Updates on COPD Research

Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) provided a progress report on the Company’s previously announced new opportunities. The Company has been moving forward in the areas of stem cell research for treatment of Chronic Obstructive Pulmonary Disease (COPD), Tumor Banking and Cancer Treatment.

The Company is in the process of forming a relationship with a medical [...]

Arch Pharmalabs Collaborates With Orochem Technologies to Manufacture an API in India

Arch Pharmalabs, Ltd., a leading provider of small molecule process R&D and full life-cycle custom synthesis and manufacturing services, announced today it has entered into a strategic partnership with Orochem Technologies, Inc., to manufacture a U.S. innovator’s active pharmaceutical ingredient (API) in late-stage clinical development using Simulated Moving Bed (SMB) technology. Orochem Technologies manufactures SMB [...]

FDA Approves Berinert for The Treatment of Hereditary Angioedema

FDA Approves Berinert to Treat Abdominal Attacks, Facial Swelling Associated With Hereditary Angioedema

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

Berinert is approved for adults and adolescents with HAE, which can occur [...]